ICH E6(R3) is coming at a time when organizations are struggling to adopt ICH E6(R2). Fundamental to these new guidelines is the modernization of processes and technology (e.g., machine learning) to clinical trials with a focus on Quality by Design and risk-based management approaches that emphasize operational efficiencies and a movement away from an overreliance on retrospective practices. Live: Tuesday, Aug. 25, 2020 1pm EDT | 12pm CDT | 10am PDT On demand available after airing until Aug. 25, 2021. Register free
Register free: http://www.appliedclinicaltrialsonline.com/act_w/benefits_ICH
Event Overview:
ICH E6(R3) is coming at a time when organizations are struggling to adopt ICH E6(R2). But should organizations wait until these guidelines are ratified to realize the intended benefits? Being proactive is diametrically opposed to the industry norm ‘wait and see’ approach, which may result in regulatory findings (e.g., 483 letters) and incur unnecessary change costs.
Fundamental to these new guidelines is the modernization of processes and technology (e.g., machine learning) to clinical trials with a focus on Quality by Design and risk-based management approaches that emphasize operational efficiencies and a movement away from an overreliance on retrospective practices.
Emphasis on quality is everywhere, but study startup is a hotspot, as it is pivotal to improving study conduct overall. Proactive planning is essential to identifying what is needed to mitigate risk, ensure regulatory compliance and audit-readiness, and in order to avoid serious budget and timeline overages which can derail a study resulting in costly rescue interventions, often due to issues that are preventable.
But what are the benefits from implementing ICH regulations now? And is change management the greatest challenge to overcome in the adoption struggle?
Key Learning Objectives:
In this webcast we will explore:
Speakers: Andy Lawton, Consultant, Risk Based Approach Ltd
Crissy MacDonald, Executive Director, Client Delivery, The Avoca Group
Elvin Thalund, Director, Industry Strategy, Oracle Health Sciences
Time and date: Tuesday, Aug. 25, 2020 1pm EDT | 12pm CDT | 10am PDT
On demand available after airing until Aug. 25, 2021.
Sponsor: Oracle Health Sciences
Register free: http://www.appliedclinicaltrialsonline.com/act_w/benefits_ICH